Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06027996 · ClinicalTrials.gov registry record · NA

Melodi Matrix™ in Breast Reconstruction

A NA study of Breast Reconstruction, sponsored by Melodi Health.

Recruiting
Registry status
NA
Development phase
702
Enrollment target
10
Study locations

NCT06027996 is a NA study of Breast Reconstruction that is actively recruiting participants, run by Melodi Health. The registered enrollment target is 702 participants, above the 355-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (98% higher). The trial reports 10 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06027996, a NA study of Breast Reconstruction, is actively recruiting participants, sponsored by Melodi Health.

RECRUITING
Registry status
NA
Development phase
702 participants
Enrollment target
10
Study locations

Study Summary

Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.

Conditions Studied

Interventions

  • DEVICE Absorbable Antibacterial Matrix

Study Locations (10)

California

  • Stanford University - Palo Alto

Michigan

  • University of Michigan Health - Ann Arbor

Minnesota

  • Mayo Clinic - Rochester

New York

  • Northwell Health - Staten Island

Ohio

  • The Ohio State University - Columbus

Pennsylvania

  • UPMC - Pittsburgh

South Carolina

  • Medical University of South Carolina - Charleston

South Dakota

  • Monument Health - Rapid City

Trial Details

FieldValue
Enrollment Target 702 participants
Start Date 2024-08-09
Est. Completion 2028-06
Phase NA

Sponsor

Melodi Health

1 total trials

What the Registry Record Tells You About NCT06027996

The ClinicalTrials.gov registry entry for NCT06027996 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 702 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 355-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (98% higher). The listed sponsor is Melodi Health, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Reconstruction appearing as the primary indexed condition, and to 1 intervention - of which Absorbable Antibacterial Matrix is the first listed.

NCT06027996 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Michigan, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06027996 about?

NCT06027996 is a clinical study titled "Melodi Matrix™ in Breast Reconstruction". Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.

What is the current status of trial NCT06027996?

This trial is currently recruiting. It is a NA study. The enrollment target is 702 participants. The study started on 2024-08-09. Estimated completion is 2028-06.

What conditions does trial NCT06027996 study?

This clinical trial studies the following conditions: Breast Reconstruction.

What interventions are being tested in trial NCT06027996?

The interventions under investigation include: Absorbable Antibacterial Matrix (DEVICE).

Who is sponsoring clinical trial NCT06027996?

This trial is sponsored by Melodi Health, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06027996 being conducted?

This trial has 10 study locations across California, Michigan, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Reconstruction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.